P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study. (1st July 2013) - Cummings, Jeffrey; Bellelli, Giuseppe; Black, Sandra; Bakchine, Serge; Krahnke, Tillmann; Strohmaier, Christine